SCHEDULE 13G/A: Harraden Circle Entities Disclose 5.32% Passive Stake in Psyence Biomedical Ltd.

Harraden Circle Investments, LLC and its affiliated entities have filed an amended Schedule 13G, reporting a passive beneficial ownership of 5.32% of Psyence Biomedical Ltd.'s Class A Common Stock as of December 31, 2024.

Summary

• Harraden Circle Investments, LLC, along with Harraden Circle Investors GP, LP, Harraden Circle Investors GP, LLC, Harraden Circle Investors, LP, Harraden Circle Special Opportunities, LP, and Frederick V. Fortmiller, Jr., collectively reported beneficial ownership of 182,323 shares of Psyence Biomedical Ltd.'s Class A Common Stock.
• This aggregate amount represents 5.32% of the Class A Common Stock outstanding.
• The reporting persons, including Frederick V. Fortmiller, Jr. as the managing member of key entities, share both voting and dispositive power over the 182,323 shares.
• The filing is an Amendment No. 5 to a Schedule 13G, indicating a passive investment purpose and not an intent to change or influence control of the issuer.
• The shares are held directly by Harraden Circle Investors, LP (91,162 shares, 2.66%) and Harraden Circle Special Opportunities, LP (91,161 shares, 2.66%).

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing disclosing passive ownership, thus it carries a neutral sentiment.

Future Outlook

This document is a passive ownership disclosure and does not contain any forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's future performance.

Industry Context

This filing is a standard regulatory disclosure of a significant passive ownership stake in a publicly traded company. It does not provide insights into broader industry trends or competitive positioning, but rather reflects an investment decision by a specific group of entities in Psyence Biomedical Ltd.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant passive ownership stakes, which can influence market perception and liquidity.

Key Dates

Keywords

Psyence Biomedical Ltd., Schedule 13G, beneficial ownership, Harraden Circle Investments, Class A Common Stock, institutional ownership, SEC filing, passive investment